Benjamin F. Edwards & Company, Inc. 10x Genomics, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in 10x Genomics, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 44,785 shares of TXG stock, worth $708,498. This represents 0.02% of its overall portfolio holdings.
Number of Shares
44,785
Previous 438
10124.89%
Holding current value
$708,498
Previous $16,000
5343.75%
% of portfolio
0.02%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TXG
# of Institutions
291Shares Held
94.7MCall Options Held
263KPut Options Held
85.1K-
Vanguard Group Inc Valley Forge, PA11MShares$174 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.8MShares$170 Million2.31% of portfolio
-
Morgan Stanley New York, NY6.48MShares$102 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.39MShares$101 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.6.37MShares$101 Million1.67% of portfolio
About 10x Genomics, Inc.
- Ticker TXG
- Exchange NASDAQ
- Sector Healthcare
- Industry Health Information Services
- Shares Outstandng 95,046,400
- Market Cap $1.5B
- Description
- 10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumabl...